{"id":98555,"date":"2026-05-20T17:27:56","date_gmt":"2026-05-20T20:27:56","guid":{"rendered":"https:\/\/murray.adv.br\/?p=98555"},"modified":"2026-05-20T17:27:56","modified_gmt":"2026-05-20T20:27:56","slug":"elea-shareholders-buy-cellera-farma-target-brazil-expansion","status":"publish","type":"post","link":"https:\/\/murray.adv.br\/en\/elea-shareholders-buy-cellera-farma-target-brazil-expansion\/","title":{"rendered":"Elea shareholders buy Cellera Farma, target Brazil expansion"},"content":{"rendered":"<section class=\"content--header\">\n<div class=\"row content-head non-featured \">\n<div class=\"title\">\n<h6 class=\"content-head__title\" style=\"text-align: center\"><em><strong>Argentine pharmaceutical group acquires 90% stake in Brazilian company; Omilton Visconde Junior retains a 10% stake and remains CEO<\/strong><\/em><\/h6>\n<\/div>\n<\/div>\n<div class=\"content__signa-share\">\n<div class=\"content__signature\">\n<div class=\"content-publication-data\">\n<div class=\"content-publication-data__text\">\n<div class=\"content-publication-data__from\"><\/div>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p class=\"content-publication-data__updated\"><time datetime=\"2026-05-20T10:25:37.328-03:00\">05\/20\/2026\u00a0<\/time><\/p>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"content__share-bar-container\">\n<div class=\"content__share-bar\"><\/div>\n<\/div>\n<\/div>\n<\/section>\n<div id=\"mc-article-body\" class=\"mc-article-body \">\n<article>\n<div class=\"no-paywall\">\n<div class=\"mc-column content-text active-extra-styles \" data-block-type=\"unstyled\" data-block-weight=\"47\" data-block-id=\"2\">\n<p class=\" content-text__container \" data-track-category=\"Link no Texto\" data-track-links=\"\" data-mrf-recirculation=\"Article links\">Shareholders of Elea, one of Argentina\u2019s largest pharmaceutical companies, finalized this week the acquisition of Cellera Farma, Brazil\u2019s youngest domestically controlled drugmaker, marking their entry into the Brazilian market and the start of an expansion plan aimed at rapid growth in the country over the coming years.<\/p>\n<\/div>\n<div class=\"wall protected-content\">\n<div class=\"mc-column content-text active-extra-styles \" data-block-type=\"unstyled\" data-block-weight=\"45\" data-block-id=\"3\">\n<p class=\" content-text__container \" data-track-category=\"Link no Texto\" data-track-links=\"\" data-mrf-recirculation=\"Article links\">At the same time, the Brazilian pharmaceutical company, whose portfolio includes brands such as Tylex, a painkiller, and Pamelor, an antidepressant, announced a distribution and commercialization agreement for two Sanofi drugs in the domestic market, a deal expected to add R$650 million in annual revenue.<\/p>\n<\/div>\n<div class=\"mc-column content-text active-extra-styles \" data-block-type=\"unstyled\" data-block-weight=\"30\" data-block-id=\"4\">\n<p class=\" content-text__container \" data-track-category=\"Link no Texto\" data-track-links=\"\" data-mrf-recirculation=\"Article links\">Under the four-year agreement with the French pharmaceutical company, which includes an option to acquire the products, Cellera will double in size and increase its annual revenue to R$1.3 billion.<\/p>\n<\/div>\n<div class=\"mc-column content-text active-extra-styles \" data-block-type=\"unstyled\" data-block-weight=\"24\" data-block-id=\"5\">\n<p class=\" content-text__container \" data-track-category=\"Link no Texto\" data-track-links=\"\" data-mrf-recirculation=\"Article links\">Cellera was founded in 2017 by businessman Omilton Visconde Junior, a well-known entrepreneur in Brazil\u2019s pharmaceutical industry, alongside private equity firm Victoria Capital Partners.<\/p>\n<\/div>\n<div class=\"mc-column content-text active-extra-styles \" data-block-type=\"unstyled\" data-block-weight=\"44\" data-block-id=\"6\">\n<p class=\" content-text__container \" data-track-category=\"Link no Texto\" data-track-links=\"\" data-mrf-recirculation=\"Article links\">The stake held by Victoria Capital, 79.9%, along with a 10% interest owned by Visconde Junior\u2019s brother, were sold to Elea\u2019s shareholders. The Brazilian executive will retain a 10% stake and remain chief executive officer, a position he has held since the company\u2019s founding.<\/p>\n<\/div>\n<div class=\"mc-column content-text active-extra-styles \" data-block-type=\"unstyled\" data-block-weight=\"47\" data-block-id=\"7\">\n<p class=\" content-text__container \" data-track-category=\"Link no Texto\" data-track-links=\"\" data-mrf-recirculation=\"Article links\">The value of the transaction, which has already been approved by Brazil\u2019s antitrust regulator CADE, was not disclosed due to a confidentiality agreement among the parties. Industry sources consulted by\u00a0<strong>Valor<\/strong>\u00a0estimated, however, that Cellera\u2019s valuation may have reached $300 million when factoring in the Sanofi agreement.<\/p>\n<\/div>\n<div class=\"mc-column content-text active-extra-styles \" data-block-type=\"unstyled\" data-block-weight=\"45\" data-block-id=\"8\">\n<p class=\" content-text__container \" data-track-category=\"Link no Texto\" data-track-links=\"\" data-mrf-recirculation=\"Article links\">At least two Elea executives, Mathias Sielecki, a shareholder and member of one of the families controlling the Argentine group, and Mariano Foglia, are relocating to Brazil and will join Cellera\u2019s management team as part of efforts to accelerate the company\u2019s growth in the country.<\/p>\n<\/div>\n<div class=\"mc-column content-text active-extra-styles \" data-block-type=\"unstyled\" data-block-weight=\"65\" data-block-id=\"9\">\n<p class=\" content-text__container \" data-track-category=\"Link no Texto\" data-track-links=\"\" data-mrf-recirculation=\"Article links\">\u201cElea is a market leader in Argentina and operates in several international markets. Entering Brazil had been an ambition for many years. It is the largest market in the region, with highly competitive and capable companies. We believe that, with our products, we can expand Cellera\u2019s portfolio and also bring a development-oriented approach,\u201d Daniel Sielecki, director and shareholder of the Argentine pharmaceutical company, told\u00a0<strong>Valor<\/strong>.<\/p>\n<\/div>\n<div class=\"mc-column content-text active-extra-styles \" data-block-type=\"unstyled\" data-block-weight=\"65\" data-block-id=\"10\">\n<p class=\" content-text__container \" data-track-category=\"Link no Texto\" data-track-links=\"\" data-mrf-recirculation=\"Article links\">According to Sielecki, the company recognizes that Brazil\u2019s pharmaceutical market is defined by intense competition, but Elea, which posts annual sales of between $700 million and $800 million, has already dealt with similar challenges. Beyond its investments in the pharmaceutical industry, both inside and outside Argentina, the Sielecki family also has businesses in sectors including oil and gas, petrochemicals and natural gas transportation through TGS.<\/p>\n<\/div>\n<div class=\"mc-column content-text active-extra-styles \" data-block-type=\"unstyled\" data-block-weight=\"34\" data-block-id=\"11\">\n<p class=\" content-text__container \" data-track-category=\"Link no Texto\" data-track-links=\"\" data-mrf-recirculation=\"Article links\">In addition to the size of the Brazilian market, Sielecki said the continued involvement of Visconde Junior and his experience in the local pharmaceutical industry would be key to executing the company\u2019s growth strategy.<\/p>\n<\/div>\n<div class=\"mc-column content-text active-extra-styles \" data-block-type=\"unstyled\" data-block-weight=\"35\" data-block-id=\"13\">\n<p class=\" content-text__container \" data-track-category=\"Link no Texto\" data-track-links=\"\" data-mrf-recirculation=\"Article links\">\u201cOur plan is to develop new products and introduce molecules that are not yet available in Brazil. We will assess the Brazilian market and determine exactly which technologies we want to bring here,\u201d he said.<\/p>\n<\/div>\n<div class=\"mc-column content-text active-extra-styles \" data-block-type=\"unstyled\" data-block-weight=\"30\" data-block-id=\"14\">\n<p class=\" content-text__container \" data-track-category=\"Link no Texto\" data-track-links=\"\" data-mrf-recirculation=\"Article links\">Visconde Junior said that initially, Cellera\u2019s strategy focused on acquiring mature drugs that no longer received significant investment from their original pharmaceutical owners and slowing or stabilizing declining sales trends.<\/p>\n<\/div>\n<div class=\"mc-column content-text active-extra-styles \" data-block-type=\"unstyled\" data-block-weight=\"50\" data-block-id=\"15\">\n<p class=\" content-text__container \" data-track-category=\"Link no Texto\" data-track-links=\"\" data-mrf-recirculation=\"Article links\">With the Sanofi agreement, however, the company faces a new challenge: Puran, a hormone replacement therapy drug, and Zinpass, used to control cholesterol, are still growing. Puran is the market leader in its segment, with a 50% market share, while Zinpass ranks second in its category, according to Cellera\u2019s CEO.<\/p>\n<\/div>\n<div data-track-category=\"multicontent\" data-track-action=\"ultimo chunk conteudo\" data-track-noninteraction=\"false\" data-track-scroll=\"view\">\n<div class=\"mc-column content-text active-extra-styles \" data-block-type=\"unstyled\" data-block-weight=\"72\" data-block-id=\"16\">\n<p class=\" content-text__container \" data-track-category=\"Link no Texto\" data-track-links=\"\" data-mrf-recirculation=\"Article links\">\u201cIt is a different level of competition. Cellera doubled in size in 2019, when it completed major acquisitions, and now it is doubling again,\u201d said Visconde Junior. \u201cThe agreement with Elea also creates the possibility of significantly expanding the portfolio and increasing our bargaining power for licensing deals in the most relevant markets,\u201d he added. According to him, an additional R$500 million in revenue is already in the company\u2019s medium-term business pipeline.<\/p>\n<p data-track-category=\"Link no Texto\" data-track-links=\"\" data-mrf-recirculation=\"Article links\">*By\u00a0Stella Fontes\u00a0\u2014 S\u00e3o Paulo<\/p>\n<p data-track-category=\"Link no Texto\" data-track-links=\"\" data-mrf-recirculation=\"Article links\">Source: Valor International<\/p>\n<p>https:\/\/valorinternational.globo.com\/<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/article>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Argentine pharmaceutical group acquires 90% stake in Brazilian company; Omilton Visconde Junior retains a 10% stake and remains CEO &nbsp; &nbsp; &nbsp; 05\/20\/2026\u00a0 Shareholders of Elea, one of Argentina\u2019s largest pharmaceutical companies, finalized this week the acquisition of Cellera Farma, Brazil\u2019s youngest domestically controlled drugmaker, marking their entry into the Brazilian market and the start [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[8106],"tags":[26928,26929],"class_list":["post-98555","post","type-post","status-publish","format-standard","hentry","category-murray-news","tag-elea-shareholders-buy-cellera-farma","tag-target-brazil-expansion"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Elea shareholders buy Cellera Farma, target Brazil expansion - Murray Advogados<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/murray.adv.br\/en\/elea-shareholders-buy-cellera-farma-target-brazil-expansion\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Elea shareholders buy Cellera Farma, target Brazil expansion - Murray Advogados\" \/>\n<meta property=\"og:description\" content=\"Argentine pharmaceutical group acquires 90% stake in Brazilian company; Omilton Visconde Junior retains a 10% stake and remains CEO &nbsp; &nbsp; &nbsp; 05\/20\/2026\u00a0 Shareholders of Elea, one of Argentina\u2019s largest pharmaceutical companies, finalized this week the acquisition of Cellera Farma, Brazil\u2019s youngest domestically controlled drugmaker, marking their entry into the Brazilian market and the start [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/murray.adv.br\/en\/elea-shareholders-buy-cellera-farma-target-brazil-expansion\/\" \/>\n<meta property=\"og:site_name\" content=\"Murray Advogados\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-20T20:27:56+00:00\" \/>\n<meta name=\"author\" content=\"Gelcy Bueno\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Gelcy Bueno\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/murray.adv.br\/en\/elea-shareholders-buy-cellera-farma-target-brazil-expansion\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/murray.adv.br\/en\/elea-shareholders-buy-cellera-farma-target-brazil-expansion\/\"},\"author\":{\"name\":\"Gelcy Bueno\",\"@id\":\"https:\/\/murray.adv.br\/en\/#\/schema\/person\/dd0d0bea46c2436124555d18c1a0d52e\"},\"headline\":\"Elea shareholders buy Cellera Farma, target Brazil expansion\",\"datePublished\":\"2026-05-20T20:27:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/murray.adv.br\/en\/elea-shareholders-buy-cellera-farma-target-brazil-expansion\/\"},\"wordCount\":681,\"keywords\":[\"Elea shareholders buy Cellera Farma\",\"target Brazil expansion\"],\"articleSection\":[\"Murray News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/murray.adv.br\/en\/elea-shareholders-buy-cellera-farma-target-brazil-expansion\/\",\"url\":\"https:\/\/murray.adv.br\/en\/elea-shareholders-buy-cellera-farma-target-brazil-expansion\/\",\"name\":\"Elea shareholders buy Cellera Farma, target Brazil expansion - Murray Advogados\",\"isPartOf\":{\"@id\":\"https:\/\/murray.adv.br\/en\/#website\"},\"datePublished\":\"2026-05-20T20:27:56+00:00\",\"author\":{\"@id\":\"https:\/\/murray.adv.br\/en\/#\/schema\/person\/dd0d0bea46c2436124555d18c1a0d52e\"},\"breadcrumb\":{\"@id\":\"https:\/\/murray.adv.br\/en\/elea-shareholders-buy-cellera-farma-target-brazil-expansion\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/murray.adv.br\/en\/elea-shareholders-buy-cellera-farma-target-brazil-expansion\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/murray.adv.br\/en\/elea-shareholders-buy-cellera-farma-target-brazil-expansion\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"In\u00edcio\",\"item\":\"https:\/\/murray.adv.br\/en\/home\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Elea shareholders buy Cellera Farma, target Brazil expansion\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/murray.adv.br\/en\/#website\",\"url\":\"https:\/\/murray.adv.br\/en\/\",\"name\":\"Murray Advogados\",\"description\":\"PLG International Lawyers\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/murray.adv.br\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/murray.adv.br\/en\/#\/schema\/person\/dd0d0bea46c2436124555d18c1a0d52e\",\"name\":\"Gelcy Bueno\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/murray.adv.br\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/1ef2acfe966d6deacdeccd2a24ea89192c41fd05fc60e57b79021358a47f5641?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/1ef2acfe966d6deacdeccd2a24ea89192c41fd05fc60e57b79021358a47f5641?s=96&d=mm&r=g\",\"caption\":\"Gelcy Bueno\"},\"url\":\"https:\/\/murray.adv.br\/en\/author\/news\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Elea shareholders buy Cellera Farma, target Brazil expansion - Murray Advogados","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/murray.adv.br\/en\/elea-shareholders-buy-cellera-farma-target-brazil-expansion\/","og_locale":"en_US","og_type":"article","og_title":"Elea shareholders buy Cellera Farma, target Brazil expansion - Murray Advogados","og_description":"Argentine pharmaceutical group acquires 90% stake in Brazilian company; Omilton Visconde Junior retains a 10% stake and remains CEO &nbsp; &nbsp; &nbsp; 05\/20\/2026\u00a0 Shareholders of Elea, one of Argentina\u2019s largest pharmaceutical companies, finalized this week the acquisition of Cellera Farma, Brazil\u2019s youngest domestically controlled drugmaker, marking their entry into the Brazilian market and the start [&hellip;]","og_url":"https:\/\/murray.adv.br\/en\/elea-shareholders-buy-cellera-farma-target-brazil-expansion\/","og_site_name":"Murray Advogados","article_published_time":"2026-05-20T20:27:56+00:00","author":"Gelcy Bueno","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Gelcy Bueno","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/murray.adv.br\/en\/elea-shareholders-buy-cellera-farma-target-brazil-expansion\/#article","isPartOf":{"@id":"https:\/\/murray.adv.br\/en\/elea-shareholders-buy-cellera-farma-target-brazil-expansion\/"},"author":{"name":"Gelcy Bueno","@id":"https:\/\/murray.adv.br\/en\/#\/schema\/person\/dd0d0bea46c2436124555d18c1a0d52e"},"headline":"Elea shareholders buy Cellera Farma, target Brazil expansion","datePublished":"2026-05-20T20:27:56+00:00","mainEntityOfPage":{"@id":"https:\/\/murray.adv.br\/en\/elea-shareholders-buy-cellera-farma-target-brazil-expansion\/"},"wordCount":681,"keywords":["Elea shareholders buy Cellera Farma","target Brazil expansion"],"articleSection":["Murray News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/murray.adv.br\/en\/elea-shareholders-buy-cellera-farma-target-brazil-expansion\/","url":"https:\/\/murray.adv.br\/en\/elea-shareholders-buy-cellera-farma-target-brazil-expansion\/","name":"Elea shareholders buy Cellera Farma, target Brazil expansion - Murray Advogados","isPartOf":{"@id":"https:\/\/murray.adv.br\/en\/#website"},"datePublished":"2026-05-20T20:27:56+00:00","author":{"@id":"https:\/\/murray.adv.br\/en\/#\/schema\/person\/dd0d0bea46c2436124555d18c1a0d52e"},"breadcrumb":{"@id":"https:\/\/murray.adv.br\/en\/elea-shareholders-buy-cellera-farma-target-brazil-expansion\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/murray.adv.br\/en\/elea-shareholders-buy-cellera-farma-target-brazil-expansion\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/murray.adv.br\/en\/elea-shareholders-buy-cellera-farma-target-brazil-expansion\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"In\u00edcio","item":"https:\/\/murray.adv.br\/en\/home\/"},{"@type":"ListItem","position":2,"name":"Elea shareholders buy Cellera Farma, target Brazil expansion"}]},{"@type":"WebSite","@id":"https:\/\/murray.adv.br\/en\/#website","url":"https:\/\/murray.adv.br\/en\/","name":"Murray Advogados","description":"PLG International Lawyers","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/murray.adv.br\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/murray.adv.br\/en\/#\/schema\/person\/dd0d0bea46c2436124555d18c1a0d52e","name":"Gelcy Bueno","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/murray.adv.br\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/1ef2acfe966d6deacdeccd2a24ea89192c41fd05fc60e57b79021358a47f5641?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/1ef2acfe966d6deacdeccd2a24ea89192c41fd05fc60e57b79021358a47f5641?s=96&d=mm&r=g","caption":"Gelcy Bueno"},"url":"https:\/\/murray.adv.br\/en\/author\/news\/"}]}},"_links":{"self":[{"href":"https:\/\/murray.adv.br\/en\/wp-json\/wp\/v2\/posts\/98555","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/murray.adv.br\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/murray.adv.br\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/murray.adv.br\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/murray.adv.br\/en\/wp-json\/wp\/v2\/comments?post=98555"}],"version-history":[{"count":2,"href":"https:\/\/murray.adv.br\/en\/wp-json\/wp\/v2\/posts\/98555\/revisions"}],"predecessor-version":[{"id":98557,"href":"https:\/\/murray.adv.br\/en\/wp-json\/wp\/v2\/posts\/98555\/revisions\/98557"}],"wp:attachment":[{"href":"https:\/\/murray.adv.br\/en\/wp-json\/wp\/v2\/media?parent=98555"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/murray.adv.br\/en\/wp-json\/wp\/v2\/categories?post=98555"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/murray.adv.br\/en\/wp-json\/wp\/v2\/tags?post=98555"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}